SG11201701028SA - Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor - Google Patents

Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor

Info

Publication number
SG11201701028SA
SG11201701028SA SG11201701028SA SG11201701028SA SG11201701028SA SG 11201701028S A SG11201701028S A SG 11201701028SA SG 11201701028S A SG11201701028S A SG 11201701028SA SG 11201701028S A SG11201701028S A SG 11201701028SA SG 11201701028S A SG11201701028S A SG 11201701028SA
Authority
SG
Singapore
Prior art keywords
receptor
antibodies directed
novel antibodies
iib
epsilon
Prior art date
Application number
SG11201701028SA
Other languages
English (en)
Inventor
Anna Carle
Carolin Direnberger
Peter Sondermann
Martina Mueller
Nicole Rieth
Thomas Pohl
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51355407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201701028S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of SG11201701028SA publication Critical patent/SG11201701028SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201701028SA 2014-08-13 2015-08-13 Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor SG11201701028SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14002825 2014-08-13
PCT/EP2015/068667 WO2016023985A1 (en) 2014-08-13 2015-08-13 Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor

Publications (1)

Publication Number Publication Date
SG11201701028SA true SG11201701028SA (en) 2017-03-30

Family

ID=51355407

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701028SA SG11201701028SA (en) 2014-08-13 2015-08-13 Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor

Country Status (19)

Country Link
US (1) US10730946B2 (zh)
EP (1) EP3180358B1 (zh)
JP (1) JP6808611B2 (zh)
KR (1) KR102424169B1 (zh)
CN (1) CN106795223B (zh)
AR (1) AR101555A1 (zh)
AU (1) AU2015303142B2 (zh)
BR (1) BR112017002755B1 (zh)
CA (1) CA2957850A1 (zh)
CL (1) CL2017000360A1 (zh)
CO (1) CO2017001384A2 (zh)
EA (1) EA035269B1 (zh)
ES (1) ES2802176T3 (zh)
IL (1) IL250569B (zh)
MX (1) MX2017001895A (zh)
MY (1) MY180940A (zh)
SG (1) SG11201701028SA (zh)
TW (1) TWI713464B (zh)
WO (1) WO2016023985A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
JP6808611B2 (ja) 2014-08-13 2021-01-06 サプレモル ゲーエムベーハー Ｆｃγ受容体ＩＩＢおよびＦｃε受容体に対する新規の抗体
WO2018036947A1 (en) * 2016-08-22 2018-03-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inhibiting biological responses induced by a receptor that uses pi3k to signal in a cell
BR112022006364A2 (pt) * 2019-10-01 2022-06-28 Epsilogen Ltd Anticorpo híbrido
CN113214392B (zh) * 2020-12-30 2022-07-01 中国人民解放军海军军医大学 抗水母毒素纳米抗体ky031、制备方法及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254753C1 (en) 2001-05-01 2008-09-18 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
AU2004293184B2 (en) * 2003-11-26 2010-12-16 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Substance binding human IgG Fc receptor IIb
WO2005115452A2 (en) * 2004-04-16 2005-12-08 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
CA2577405A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
NZ618016A (en) 2011-05-21 2015-05-29 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
JP6808611B2 (ja) 2014-08-13 2021-01-06 サプレモル ゲーエムベーハー Ｆｃγ受容体ＩＩＢおよびＦｃε受容体に対する新規の抗体

Also Published As

Publication number Publication date
JP6808611B2 (ja) 2021-01-06
EP3180358B1 (en) 2020-04-01
MX2017001895A (es) 2017-08-28
CO2017001384A2 (es) 2017-05-10
AU2015303142A1 (en) 2017-03-02
AU2015303142B2 (en) 2020-08-06
WO2016023985A1 (en) 2016-02-18
TWI713464B (zh) 2020-12-21
US10730946B2 (en) 2020-08-04
ES2802176T3 (es) 2021-01-15
AR101555A1 (es) 2016-12-28
CN106795223B (zh) 2021-05-04
BR112017002755A2 (pt) 2017-12-19
TW201629099A (zh) 2016-08-16
EA201790314A1 (ru) 2017-06-30
US20170226208A1 (en) 2017-08-10
MY180940A (en) 2020-12-14
EP3180358A1 (en) 2017-06-21
JP2017529832A (ja) 2017-10-12
KR102424169B1 (ko) 2022-07-25
CL2017000360A1 (es) 2017-07-14
KR20170041250A (ko) 2017-04-14
EA035269B1 (ru) 2020-05-22
IL250569A0 (en) 2017-03-30
CA2957850A1 (en) 2016-02-18
IL250569B (en) 2021-05-31
BR112017002755B1 (pt) 2023-12-26
CN106795223A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
IL285287B1 (en) Antibodies to tigit
IL285101A (en) G protein-coupled receptor-directed antibodies and methods of use
IL250415A0 (en) Antibodies against pd-l1
IL246661A0 (en) Human antibodies to pd–l1
HK1253695A1 (zh) T細胞受體特異性抗體
HK1255160A1 (zh) 取代的4-氮雜吲哚以及它們作為glun2b受體調節劑的用途
FI3169703T4 (fi) Kimeerinen antigeenireseptori ja sen käyttö
SG11201701028SA (en) Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor
HRP20180664T1 (hr) Nova protutijela protiv receptora fc-gama iib i njihova upotreba
AU2014902457A0 (en) Chimeric antigen receptor and uses thereof